Key Points
- President Nadir Mahmood sold 5,649 shares of Nkarta on Jan. 15 at an average price of $2.07 for about $11,693, reducing his stake to 167,727 shares (a 3.26% ownership decrease).
- Nkarta shares trade around $2.04 with a 52-week range of $1.31–$2.74 and a market cap of about $145 million, while analysts show mixed ratings but an average price target of $13.25.
- Nkarta is a clinical-stage biotech developing off-the-shelf natural killer (NK) cell therapies, with its lead program NKX019 (an anti-CD19 CAR-NK) in early-phase trials for B‑cell malignancies.
Nkarta, Inc. (NASDAQ:NKTX - Get Free Report) President Nadir Mahmood sold 5,649 shares of Nkarta stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $2.07, for a total value of $11,693.43. Following the completion of the transaction, the president directly owned 167,727 shares of the company's stock, valued at $347,194.89. This represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Nkarta Stock Performance
NKTX opened at $2.04 on Wednesday. Nkarta, Inc. has a 52-week low of $1.31 and a 52-week high of $2.74. The firm has a market cap of $144.90 million, a P/E ratio of -1.48 and a beta of 0.60. The business's fifty day moving average is $1.88 and its 200-day moving average is $2.03.
Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.03. On average, research analysts predict that Nkarta, Inc. will post -1.7 earnings per share for the current fiscal year.
Analysts Set New Price Targets
NKTX has been the topic of several analyst reports. Stifel Nicolaus reduced their price target on shares of Nkarta from $12.00 to $11.00 and set a "buy" rating on the stock in a research report on Tuesday, November 11th. Wall Street Zen upgraded Nkarta from a "sell" rating to a "hold" rating in a research note on Saturday, December 20th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Nkarta in a research note on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Nkarta has an average rating of "Moderate Buy" and an average target price of $13.25.
Read Our Latest Research Report on NKTX
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Savant Capital LLC bought a new position in shares of Nkarta in the 2nd quarter valued at $36,000. SG Americas Securities LLC increased its holdings in Nkarta by 35.0% in the 3rd quarter. SG Americas Securities LLC now owns 23,663 shares of the company's stock worth $49,000 after purchasing an additional 6,141 shares in the last quarter. CWM LLC raised its position in Nkarta by 23.4% in the second quarter. CWM LLC now owns 34,758 shares of the company's stock valued at $58,000 after purchasing an additional 6,601 shares during the last quarter. Bailard Inc. acquired a new stake in shares of Nkarta during the third quarter valued at about $61,000. Finally, Forefront Analytics LLC grew its holdings in shares of Nkarta by 41.0% during the third quarter. Forefront Analytics LLC now owns 39,452 shares of the company's stock worth $82,000 after purchasing an additional 11,473 shares during the last quarter. 80.54% of the stock is currently owned by institutional investors and hedge funds.
Nkarta Company Profile
(
Get Free Report)
Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company's platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.
Nkarta's lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
